美国 · SEC FORM 4
OMEROS CORP
OMER · Nasdaq · CIK 0001285819 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
27 同一窗口内观察到的 Form 4 交易行
12 sales · 15 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-11-17 · Demopulos Gregory A MD.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 11,382,531
- 上期报告
- 12,491,576
- 日均成交量
- 1,638,478
- 回补天数
- 7.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
Form 4 申报证据
32 transaction lines in the latest 365-day window; 72 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Borges David J. | 卖出 (S) | Common Stock | 10,000 | USD 20.95 | USD 209,500 | SEC 申报 ↗ |
| 2026-09-23 | Borges David J. | 期权行权／转换 (M) | Common Stock | 10,000 | USD 15.58 | USD 155,800 | SEC 申报 ↗ |
| 2026-09-22 | Borges David J. | 卖出 (S) | Common Stock | 10,000 | USD 20.95 | USD 209,500 | SEC 申报 ↗ |
展开近期 Form 4 证据 (27 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Borges David J. | 卖出 (S) | Common Stock | 10,000 | USD 20.95 | USD 209,500 | SEC 申报 ↗ |
| 2026-09-23 | Borges David J. | 期权行权／转换 (M) | Common Stock | 10,000 | USD 15.58 | USD 155,800 | SEC 申报 ↗ |
| 2026-09-22 | Borges David J. | 卖出 (S) | Common Stock | 10,000 | USD 20.95 | USD 209,500 | SEC 申报 ↗ |
| 2026-09-22 | Borges David J. | 期权行权／转换 (M) | Common Stock | 10,000 | USD 3.44 | USD 34,350 | SEC 申报 ↗ |
| 2026-08-31 | Cancelmo Peter B | 卖出 (S) | Common Stock | 25,000 | USD 18.54 | USD 463,500 | SEC 申报 ↗ |
| 2026-08-31 | Cancelmo Peter B | 期权行权／转换 (M) | Common Stock | 25,000 | USD 2.94 | USD 73,500 | SEC 申报 ↗ |
| 2026-08-28 | Cancelmo Peter B | 卖出 (S) | Common Stock | 25,000 | USD 18.65 | USD 466,250 | SEC 申报 ↗ |
| 2026-08-28 | Cancelmo Peter B | 期权行权／转换 (M) | Common Stock | 25,000 | USD 2.94 | USD 73,500 | SEC 申报 ↗ |
| 2026-08-27 | HANISH ARNOLD C | 卖出 (S) | Common Stock | 10,000 | USD 18.95 | USD 189,500 | SEC 申报 ↗ |
| 2026-08-27 | HANISH ARNOLD C | 期权行权／转换 (M) | Common Stock | 10,000 | USD 14.95 | USD 149,475 | SEC 申报 ↗ |
| 2026-08-26 | HANISH ARNOLD C | 卖出 (S) | Common Stock | 5,000 | USD 18.53 | USD 92,650 | SEC 申报 ↗ |
| 2026-08-26 | HANISH ARNOLD C | 期权行权／转换 (M) | Common Stock | 5,000 | USD 15.81 | USD 79,050 | SEC 申报 ↗ |
| 2026-08-24 | Borges David J. | 卖出 (S) | Common Stock | 906 | USD 19.10 | USD 17,305 | SEC 申报 ↗ |
| 2026-08-24 | Borges David J. | 期权行权／转换 (M) | Common Stock | 906 | USD 2.94 | USD 2,664 | SEC 申报 ↗ |
| 2026-08-21 | Borges David J. | 卖出 (S) | Common Stock | 10,000 | USD 18.95 | USD 189,500 | SEC 申报 ↗ |
| 2026-08-21 | Borges David J. | 期权行权／转换 (M) | Common Stock | 10,000 | USD 3.52 | USD 35,247 | SEC 申报 ↗ |
| 2026-08-20 | Cable Thomas J. | 卖出 (S) | Common Stock | 15,000 | USD 18.45 | USD 276,750 | SEC 申报 ↗ |
| 2026-08-20 | Cable Thomas J. | 期权行权／转换 (M) | Common Stock | 15,000 | USD 2.96 | USD 44,475 | SEC 申报 ↗ |
| 2026-08-13 | Borges David J. | 卖出 (S) | Common Stock | 5,000 | USD 16.95 | USD 84,750 | SEC 申报 ↗ |
| 2026-08-13 | Borges David J. | 期权行权／转换 (M) | Common Stock | 5,000 | USD 3.93 | USD 19,650 | SEC 申报 ↗ |
| 2026-05-22 | Cable Thomas J. | 卖出 (S) | Common Stock | 7,500 | USD 11.61 | USD 87,075 | SEC 申报 ↗ |
| 2026-05-22 | Cable Thomas J. | 期权行权／转换 (M) | Common Stock | 7,500 | USD 10.84 | USD 81,300 | SEC 申报 ↗ |
| 2026-02-18 | Demopulos Gregory A MD | 期权行权／转换 (M) | Common stock | 400,000 | USD 10.27 | USD 4,108,000 | SEC 申报 ↗ |
| 2026-02-18 | Demopulos Gregory A MD | 代扣税 (F) | Common stock | 357,678 | USD 11.93 | USD 4,267,099 | SEC 申报 ↗ |
| 2026-01-13 | Borges David J. | 卖出 (S) | Common stock | 30,000 | USD 12.31 | USD 369,300 | SEC 申报 ↗ |
| 2026-01-13 | Borges David J. | 期权行权／转换 (M) | Common stock | 30,000 | USD 3.06 | USD 91,800 | SEC 申报 ↗ |
| 2026-01-12 | Borges David J. | 卖出 (S) | Common stock | 30,000 | USD 12.72 | USD 381,600 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | OMER |
| CIK | 0001285819 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 72 transaction lines from 2020-03-13 to 2026-09-23 2 P purchase lines · 28 S sale lines · 42 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.